Kailera Therapeutics
About Kailera Therapeutics
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a broad and advanced therapeutic pipeline that is poised to deliver differentiated treatment options for obesity and related conditions.
Recent News
Keep an Eye on These 15 Biotech Companies in 2026
Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk: PitchBook
The 5 Largest IPOs in Biopharma History
Kailera IPO Interview: CEO Renaud Talks Biotech Market, China and Obesity Pipeline
The IPO Pipeline Finally Gets Interesting
Labiotech’s 15 Biopharma Companies to Watch in 2026
Biotech’s IPO Tide Is Finally Turning, Thanks in Part to the Recent M&A Surge
Kailera Therapeutics' $625 Million IPO Sets Record as Largest Biotech Offering
JPMorgan Chase & Co. $JPM Shares Sold by Brookwood Investment Group LLC
Nine Biotech Companies that Could Revolutionize Obesity Treatments
VCs Redirect Billions to Biotech as Hedge Against AI Bubble, PitchBook Reports
STAT+: FDA Eyes Expanding Testosterone Therapy for Libido
Kailera Therapeutics IPO Raises $718.8M for Obesity Drug Pipeline
Kailera Therapeutics IPO Priced at $16, Opens at $26 Targeting Obesity Market
Obesity Treatment Firm Kailera Upsizes IPO to Raise $625 Million
Hengrui, Kailera Tout Positive Results for Dual-Acting Obesity Pill
Merck Launches Idvynso as Kailera Therapeutics Sets Record $625M Biotech IPO
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
Biotech Has Become a Good News Story. Let the Sun Shine
Kailera Therapeutics Prices $625 M IPO at $16 per Share
Post-IPO, Kailera Looks Beyond Obesity to MASH
Eli Lilly and Company $LLY Shares Acquired by Freestone Capital Holdings LLC
Kailera Therapeutics Raises $625 Million in Record Biotech IPO
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
STAT+: Kailera’s Own ‘Triple-G’ Drug Also Looks Very Powerful
Using AI To Personalize Healthcare–Without Losing Patient Trust
Kailera Raises $625M IPO in Biotech Record
Recent Deals
Kailera Raises $1bn in Growth-Stage Funding Round
Kailera Therapeutics Files IPO to Fund Dual GLP-1/GIP Obesity Drug Development
Kailera Therapeutics Secures $600M Series B Funding Led by Bain Capital Private Equity
Kailera Therapeutics Eyes Record $533M IPO to Target Obesity Market
Kailera Therapeutics Raises $718.8M in IPO, Launches on Nasdaq